[go: up one dir, main page]

SG11201903801YA - Pyridone compound as c-met inhibitor - Google Patents

Pyridone compound as c-met inhibitor

Info

Publication number
SG11201903801YA
SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA
Authority
SG
Singapore
Prior art keywords
met inhibitor
pyridone compound
met
pyridone
compound
Prior art date
Application number
SG11201903801YA
Other languages
English (en)
Inventor
Xiongbin Xu
Gang Li
Charles Z Ding
Lihong Hu
Guoping Hu
Jian Li
Shuhui Chen
Zhigang Chi
Kun Wang
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201903801Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of SG11201903801YA publication Critical patent/SG11201903801YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SG11201903801YA 2016-10-27 2017-10-27 Pyridone compound as c-met inhibitor SG11201903801YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27
PCT/CN2017/107964 WO2018077227A1 (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Publications (1)

Publication Number Publication Date
SG11201903801YA true SG11201903801YA (en) 2019-05-30

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903801YA SG11201903801YA (en) 2016-10-27 2017-10-27 Pyridone compound as c-met inhibitor

Country Status (28)

Country Link
US (1) US10501443B2 (ru)
EP (1) EP3533787B1 (ru)
JP (1) JP6719679B2 (ru)
KR (1) KR102070748B1 (ru)
CN (1) CN109311812B (ru)
AU (1) AU2017348810B2 (ru)
BR (1) BR112019008415B1 (ru)
CA (1) CA3041164C (ru)
CO (1) CO2019005165A2 (ru)
DK (1) DK3533787T3 (ru)
EA (1) EA038108B1 (ru)
ES (1) ES2835301T3 (ru)
HR (1) HRP20201985T1 (ru)
HU (1) HUE051734T2 (ru)
IL (1) IL266126B (ru)
LT (1) LT3533787T (ru)
MX (1) MX374439B (ru)
MY (1) MY189557A (ru)
PE (1) PE20190912A1 (ru)
PH (1) PH12019500875B1 (ru)
PL (1) PL3533787T3 (ru)
PT (1) PT3533787T (ru)
RS (1) RS61126B1 (ru)
SG (1) SG11201903801YA (ru)
SI (1) SI3533787T1 (ru)
UA (1) UA122737C2 (ru)
WO (1) WO2018077227A1 (ru)
ZA (1) ZA201903074B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019206268A1 (zh) * 2018-04-26 2019-10-31 福建广生堂药业股份有限公司 一种c-MET抑制剂的晶型及其盐型和制备方法
WO2020156453A1 (zh) * 2019-02-01 2020-08-06 南京明德新药研发有限公司 作为c-Met抑制剂的含嘧啶基团的三并环类化合物
CN116171156A (zh) * 2020-07-31 2023-05-26 南京明德新药研发有限公司 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
US20240277711A1 (en) 2021-06-04 2024-08-22 Merck Patent Gmbh Compounds for the treatment of glioblastoma
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002519A2 (en) * 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company THROMBIN OR FACTOR Xa INHIBITORS
JPWO2005085200A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体
JP2010519204A (ja) * 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
CN104144925A (zh) 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮
KR20140138984A (ko) * 2012-03-19 2014-12-04 메르크 파텐트 게엠베하 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 기타 항종양 화합물과의 조합
WO2014056566A1 (en) * 2012-10-11 2014-04-17 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor
SG11201704763SA (en) * 2014-12-11 2017-07-28 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative

Also Published As

Publication number Publication date
LT3533787T (lt) 2020-11-25
KR102070748B1 (ko) 2020-01-29
HRP20201985T1 (hr) 2021-02-05
KR20190058678A (ko) 2019-05-29
HUE051734T2 (hu) 2021-03-29
UA122737C2 (uk) 2020-12-28
RS61126B1 (sr) 2020-12-31
DK3533787T3 (da) 2020-11-30
JP2019535806A (ja) 2019-12-12
MY189557A (en) 2022-02-16
MX374439B (es) 2025-03-06
MX2019004626A (es) 2019-11-08
ZA201903074B (en) 2020-01-29
US10501443B2 (en) 2019-12-10
CN109311812B (zh) 2020-03-17
CN109311812A (zh) 2019-02-05
PH12019500875A1 (en) 2019-06-17
PH12019500875B1 (en) 2024-03-01
CA3041164A1 (en) 2018-05-03
PE20190912A1 (es) 2019-06-26
AU2017348810A1 (en) 2019-05-23
IL266126A (en) 2019-06-30
IL266126B (en) 2020-07-30
BR112019008415A2 (pt) 2019-07-09
NZ753020A (en) 2021-08-27
US20190248763A1 (en) 2019-08-15
EP3533787A4 (en) 2019-11-13
EP3533787A1 (en) 2019-09-04
PT3533787T (pt) 2020-11-20
JP6719679B2 (ja) 2020-07-08
SI3533787T1 (sl) 2021-01-29
AU2017348810B2 (en) 2020-05-07
CA3041164C (en) 2019-12-17
ES2835301T3 (es) 2021-06-22
PL3533787T3 (pl) 2021-03-08
CO2019005165A2 (es) 2019-05-31
BR112019008415B1 (pt) 2020-09-29
EP3533787B1 (en) 2020-09-30
EA038108B1 (ru) 2021-07-07
WO2018077227A1 (zh) 2018-05-03
EA201990952A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
SG11201903801YA (en) Pyridone compound as c-met inhibitor
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
ZA202206923B (en) New methylquinazolinone derivatives
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MY180083A (en) Tetrahydropyrrolothiazine compounds
PH12017501523A1 (en) Selective bace1 inhibitors
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MY194116A (en) Pharmaceutical compounds
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
JO3318B1 (ar) مثبطات bace
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
PH12016502246B1 (en) Carboxamide derivatives
MX2018014813A (es) Composiciones antibacterianas.
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor